|
Market Closed -
Swiss Exchange
11:30:15 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 0.0208 CHF | -7.96% |
|
-7.96% | -62.45% |
| 10-08 | Swiss Market Index Retreats; Novartis Shares Decline | MT |
| 10-08 | Addex Therapeutics' Neurosterix to Advance Schizophrenia Drug to Phase 2 Trials | MT |
Company Valuation: Addex Therapeutics Ltd
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 53.24 | 39.42 | 10.39 | 6.181 | 5.624 | 6.458 |
| Change | - | -25.96% | -73.65% | -40.48% | -9.01% | 14.83% |
| Enterprise Value (EV) 1 | 35.11 | 19.42 | 3.801 | 2.66 | 2.324 | 4.854 |
| Change | - | -44.7% | -80.42% | -30.02% | -12.62% | 108.84% |
| P/E | -4.13x | -2.31x | -0.22x | -0.32x | 0.8x | -0.88x |
| PBR | 3.69x | 2.33x | 1.58x | 5.03x | 0.58x | 1.37x |
| PEG | - | 0.35x | -0.09x | 0x | -0x | 0x |
| Capitalization / Revenue | 13.7x | 12.5x | 7.19x | 3.75x | 13.7x | 37.4x |
| EV / Revenue | 9.05x | 6.16x | 2.63x | 1.62x | 5.67x | 28.1x |
| EV / EBITDA | -2.87x | -1.25x | -0.19x | -0.26x | -0.91x | -1.72x |
| EV / EBIT | -2.87x | -1.25x | -0.19x | -0.26x | -0.84x | -1.72x |
| EV / FCF | -4.47x | -2.37x | -0.42x | -0.63x | -0.77x | -3.83x |
| FCF Yield | -22.4% | -42.2% | -240% | -159% | -130% | -26.1% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.4819 | -0.4499 | -0.4604 | -0.1421 | 0.0719 | -0.0627 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3.879 | 3.153 | 1.445 | 1.647 | 0.41 | 0.1729 |
| EBITDA 1 | -12.22 | -15.48 | -20.49 | -10.26 | -2.563 | -2.814 |
| EBIT 1 | -12.24 | -15.51 | -20.52 | -10.28 | -2.755 | -2.815 |
| Net income 1 | -12.86 | -15.35 | -20.8 | -10.56 | 7.056 | -6.728 |
| Net Debt 1 | -18.13 | -20 | -6.584 | -3.521 | -3.3 | -1.604 |
| Reference price 2 | 1.9900 | 1.0400 | 0.1006 | 0.0460 | 0.0572 | 0.0554 |
| Nbr of stocks (in thousands) | 26,754 | 37,903 | 103,234 | 134,374 | 98,324 | 116,571 |
| Announcement Date | 3/11/21 | 3/10/22 | 3/30/23 | 4/18/24 | 5/15/25 | 4/30/26 |
1CHF in Million2CHF
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 5.59M | |
| 17.43x | 6.6x | 12.65x | 1.71% | 65.94B | |
| 30.07x | 8.27x | 26.77x | 0.06% | 56.88B | |
| 38.45x | 6.85x | 20.42x | 0.85% | 56.53B | |
| 49.29x | 6.27x | 34.36x | -.--% | 46.49B | |
| 35.48x | 3.35x | 14.48x | -.--% | 44.8B | |
| -22.45x | 63.4x | -21.48x | -.--% | 41.59B | |
| 35.89x | 8.84x | 23.03x | 0.37% | 35.35B | |
| 37.6x | 8.06x | 26.12x | -.--% | 33.29B | |
| -69.1x | 13.21x | -71.01x | -.--% | 25.1B | |
| Average | 16.96x | 13.87x | 7.26x | 0.33% | 40.6B | |
| Weighted average by Cap. | 21.59x | 13.01x | 11.74x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ADXN Stock
- Valuation Addex Therapeutics Ltd
Select your edition
All financial news and data tailored to specific country editions
